Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens-Reference-Cited by-同舟云学术

Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens

Published:2012-11-26 Issue:11 Volume:7 Page:e50307
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Scherrer Alexandra U.,Böni Jürg,Yerly Sabine,Klimkait Thomas,Aubert Vincent,Furrer Hansjakob,Calmy Alexandra,Cavassini Matthias,Elzi Luigia,Vernazza Pietro L.,Bernasconi Enos,Ledergerber Bruno,Günthard Huldrych F.,

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART;RS Hogg;PLoS Med,2006

2. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen;A Cozzi-Lepri;AIDS,2007

3. Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa;CJ Hoffmann;Clin Infect Dis,2009

4. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia;S Napravnik;J Acquir Immune Defic Syndr,2005

5. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda;SJ Reynolds;Antivir Ther,2009

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C;PLOS Computational Biology;2021-09-07

2. Comparing mutational pathways to lopinavir resistance in HIV-1 subtypes B versus C;2020-09-25

3. Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals;JAIDS Journal of Acquired Immune Deficiency Syndromes;2019-11-01

4. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study;The Lancet HIV;2019-09

5. Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes;JAIDS Journal of Acquired Immune Deficiency Syndromes;2018-04-01